Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trialsSolange Peters, Mary O’Brien, Baktiar Hasan et al.|Lung Cancer|2021Cited by 9
P-149 Impact of sequence of biologic therapies on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC): an exploratory, retrospective pooled analysisAlberto F. Sobrero, Marc Peeters, Jean‐Yves Douillard et al.|Annals of Oncology|2016Cited by 2